Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A method to select chemically modified aptamers directly.

C Boiziau1, J J Toulmé

  • 1Laboratoire de Biophysique Moléculaire, INSERM U 386, Université Victor Segalen Bordeaux 2, France. claudine.boiziau@bordeaux.inserm.fr

Antisense & Nucleic Acid Drug Development
|February 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New injectable self-assembled hydrogels that promote angiogenesis through a bioactive degradation product.

Acta biomaterialia·2020
Same author

Driving in vitro selection of anti-HIV-1 TAR aptamers by magnesium concentration and temperature.

Combinatorial chemistry & high throughput screening·2002
Same author

New ways of initiating translation in eukaryotes.

Molecular and cellular biology·2001
Same author

Gel renaturation assay for ribonucleases.

Methods in enzymology·2001
Same author

RNA and N3'-->P5' kissing aptamers targeted to the trans-activation responsive (TAR) RNA of the human immunodeficiency virus-1.

Nucleosides, nucleotides & nucleic acids·2001
Same author

Modulation of RNA function by oligonucleotides recognizing RNA structure.

Progress in nucleic acid research and molecular biology·2001
Same journal

Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.

Antisense & nucleic acid drug development·2003
Same journal

Safety of CpG oligodeoxynucleotides in veterinary species.

Antisense & nucleic acid drug development·2003
Same journal

Coupling of RNAi-mediated target downregulation with gene replacement.

Antisense & nucleic acid drug development·2003
Same journal

Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells.

Antisense & nucleic acid drug development·2003
Same journal

Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo.

Antisense & nucleic acid drug development·2003
Same journal

Effects of base modifications on antisense properties of 2'-O-methoxyethyl and PNA oligonucleotides.

Antisense & nucleic acid drug development·2003
See all related articles

This study introduces a novel method for selecting nuclease-resistant aptamers. The technique uses DNA hybridization to indirectly amplify modified RNA aptamer candidates, improving their stability for therapeutic applications.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Drug Discovery

Background:

  • In vitro selection identifies high-affinity aptamers but often yields unmodified sequences with short biological half-lives.
  • Limited incorporation of nuclease-resistant modified nucleotides by polymerases hinders aptamer stability.
  • Developing alternative methods for selecting nuclease-resistant aptamers is crucial for therapeutic applications.

Purpose of the Study:

  • To describe a novel method for selecting nuclease-resistant aptamers.
  • To overcome limitations of standard in vitro selection for generating stable aptamers.
  • To enable the identification of modified aptamers with enhanced ex vivo and in vivo stability.

Main Methods:

  • Selection of 2'O-methyl RNA oligonucleotides against the HIV-1 TAR RNA structure.

Related Experiment Videos

  • DNA 'fishing' using Watson-Crick hybridization to isolate complementary DNA sequences.
  • Indirect amplification of modified aptamer candidates via PCR and re-selection.

    • Main Results:

    • Successfully adapted in vitro selection to identify nuclease-resistant aptamer candidates.
    • Developed a method for indirect amplification of chemically modified oligonucleotides.
    • Enriched pool of modified sequences suitable for subsequent selection rounds.

    Conclusions:

    • The described method allows for the selection of nuclease-resistant aptamers.
    • This approach enhances aptamer stability, expanding their potential therapeutic applications.
    • The indirect amplification strategy overcomes limitations of direct incorporation of modified nucleotides.